High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?
| Authors | |
|---|---|
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Clinical lymphoma, myeloma & leukemia |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1016/j.clml.2013.09.004 |
| Field | Oncology and hematology |
| Keywords | Cytogenetics; GEP; High-risk disease; MGUS; Multiple myeloma; Prognosis |
| Description | Multiple myeloma (MM) is a clonal plasma cell malignancy. Although MM is still not completely curable, it can be maintained at the level of a long-term chronic condition. Irrespective of the treatment strategy, relapse is still a major problem for most patients. Approximately 10% to 15% of all MM patients relapse early and have poor prognosis and outcome. Currently, there are many ways of identifying these high-risk patients using cytogenetics or molecular biology. Despite these various approaches to definition of high risk patients, a clear definition of high-risk MM has not been widely accepted. In this review, we discuss and compare various approaches, and their strengths and weaknesses in early identification of high-risk MM patients. |
| Related projects: |
|